Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Multiple Myeloma Physicians

Articles with lock require a subscription to GLG News | Request a free trial
Donald FlemingMay 7, 2008
Hedgehog pathwa drugs and chemotherapy
Analysis of: Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Hedgehog path new and will improve on chemo/biologic therapy available for colorectal cance Past attempts at ading to regimens have not always been successful ie PACE
May 7, 2008
Genomics are coming! Are we ready?
Analysis of: Cancer-Gene Test Boosts Myriad's Sales | online.wsj.com
Author: GLG Expert Contributor
Myriad Genetics Inc. went directly to the patients who then were tested whether the tests were indicated or paid for by insurers or out of their own pockets. If patients have "medical savings accts" as suggested by various political candidates, right or wrong patients will want it with this kind...
May 6, 2008
Curis, Inc (CRIS, NASDAQ) & Genentech in partnership Re: a hedgehog antagonist in colon cancer
Analysis of: Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
GDC-0449 is an oral agent that will be added to "standard" therapy in metastatic colorectal carcinoma (CRC) and evaluating progression free survival as the primary objective.
May 6, 2008
Amplimed (?) anything for pancreatic ca would be worthwile.
Analysis of: AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
An interesting randomized phase II trial of Gemzar (the current standard with Tarceva) vs imexon + Gemzar. BUT shouldn't it be compared to Gemzar/ Tarceva??
May 5, 2008
Ricin Vaccine Market Relies on Threat of Terror
Analysis of: DOR BioPharma Initiates Non-Human Primate Efficacy Studies of RiVaxTM, Its Vaccine Against Ricin Toxin | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Ricin is an extraordinarily potent toxin that is fatal because of its ability to inhibit protein synthesis and rapidly cause multisystem failure.  Because ricin can be prepared from castro beans, it has the potential to be used in terrorist attacks.  The present vaccine has the potential to...
May 5, 2008
Too Early to Draw Conclusions Yet on Vargatef
Analysis of: Data suggests promising overall survival and progression-free survival with Vargatef(TM) (BIBF 1120) | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Vargatef is a novel angiokinase inhibitor that blocks VEGF, PDGR and FGF receptors.  The current phase II study in patients with non small cell lung cancer shows that this oral agent can be given safely.  It is far too early to draw conclusions regarding efficacy.
May 5, 2008
AstraZeneca's (AZ) IRESSA still alive in Europe.....? There is life after failure in the US.
Analysis of: AstraZeneca Files Marketing Application in Europe for EGFR Inhibitor Gefitinib (IRESSA(TM)) in Locally Advanced Pre-Treated Non-Small Cell Lung Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Approval will be base on the phase III INTEREST trial that showed in NSCLC that Iressa was "non-inferior" to standard chemotherapy after platinum therapy failure first line. Iressa was better tolerated and had an improved quality of life.
May 5, 2008
BITE antibodies for solid tumors: Still more bark than bite!!!
Analysis of: Micromet Enrolls First Patient in Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors | www.pipelinereview.com
Author: GLG Expert Contributor
Micromet's Bite antibodies strategy garners the patient's T-cells to attack tumor cells. This technology showed proof of principle i hematological malignancies , and now a Phase I clinical trial has commenced for solid tumors. The rationale is intriguing, but immunotherapy has been elusive in solid...
May 1, 2008
Genomics!!! I told you so......
Analysis of: New Study Ties Genes To Leukemia Treatment | online.wsj.com
Author: GLG Expert Contributor
Gene mutation analysis can help refine therapy in acute leukemia and impact on results!!
April 30, 2008
Rituxan ( Vitamin R ): Let's not panic!!
Analysis of: Wider Aim for Rituxan Fails | online.wsj.com
Author: GLG Expert Contributor
Rituxan failed to improve various parameters and targets in a rather comprehensive study of patients with Lupus.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next91 to 100 of 836

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-30T05:45:15.877